Navtemadlin,Ruxolitinib
Kartos Therapeutics,novartis,incyte
['mpnsm', '#mpn', 'navtemadlin', 'rux,(-crux),(-trux),(-deruxtecan)', 'ruxolitinib', '#myelof', 'rux,(-crux),(-trux)']
improvements in spleen volume reduction were observed with #ruxolitinib + navtemadlin in patients with primary or secondary tp53 wild-type #myelofibrosis who experienced suboptimal response to ruxolitinib alone. #eha2023 #mpnsm | 
Oncology news and insights from leading researchers and cancer centers.